Biodesix(BDSX) - 2023 Q4 - Annual Results

Exhibit 99.1 Persistent, high double-digit growth in Lung Diagnostic test volume - growing 65% in FY2023 versus FY2022 - and the sixth consecutive quarter with greater than 50% year-over-year growth; 2024 Total Revenue Guidance of $65 million to $68 million; Conference Call and Webcast Today at 8:30 a.m. ET "I am exceptionally proud of the Biodesix team and our record of accomplishments in 2023," said Scott Hutton, CEO of Biodesix. "We were focused on three goals: driving increased revenue through adoption ...